TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05619315

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Charcoal -based whitening toothpaste
Description: The labial surface of anterior teeth will be brushed by the circular brushing technique twice daily (morning and after 6 hours) for at least 1 minute using charcoal containing toothpaste. Soft bristles toothbrushes will provided to all patients. After 1 month, re-evaluation of the stains will be performed and the data will be recorded.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Calcium carbonate /perlite containing whitening toothpaste.
Description: The labial surface of anterior teeth will be brushed by the circular brushing technique twice daily (morning and after 6hours) for at least 1 minute using (calcium carbonate /perlite) containing toothpaste. Soft bristles toothbrushes will provided to all patients. After 1 month, re-evaluation of the stains will be performed and the data will be recorded.
Study: NCT05272553

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Narrative Exposure Therapy
Description: NET (Schauer et al., 2011) is an evidence-based, short-term, manualised treatment for trauma-spectrum disorders; it aims to reduce symptoms of traumatic stress in individuals who continue to suffer from past experiences of traumatic stressors; NET combines principles of CBT, Testimony Therapy, and Exposure Therapy.
Study: NCT05795491

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Azole Antifungal
Description: Azole antifungals are a group of medicines that contain an azole ring and inhibit the growth of a wide range of fungi
Study: NCT05936021

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Algorithm model-based Aranesp doses
Description: Patients will receive doses calculated by the algorithm instead of by the standard of care procedures. Model-based Aranesp doses will be computed at the same time that doses based on the dialysis anemia protocol are determined. The model-based doses will be administered instead of the protocol-based doses and in the same way and at the same time as the protocol-based doses would have been. The model-based dosing will be more flexible than the protocol-based dosing. Some constraints in the protocol-based dosing were created to prevent patients from achieving high Hb levels. The model-based dosing will also prevent these high Hb values but will do so by predicting a patient's Hb level into the future and then using these predictions to determine doses to reduce Hb variability and to reduce the amount of Aranesp used.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard of care
Description: Current standard of care guidelines are followed for erythropoiesis-stimulating agents to control anemia in dialysis patients
Study: NCT06477081

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: FS-LASIK procedure
Description: For the FS-LASIK technique, the following steps will be followed: application of topical anesthesia to mitigate discomfort and pain throughout the procedure, and the patient will be covered with a sterile drape. Subsequently, the patient will be aligned to artificially flatten the entire corneal surface, ensuring head stability with a slight tilt to optimize surgical access and avoid nasal interference. The femtosecond laser system use will be the ATOS operating system (Schwind eye-tech-solutions, Mainparkstraße 6-10, 63801 Kleinostheim, Germany), which is responsible for creating a corneal incision to create the flap, with controlled precision to ensure proper separation of corneal layers. The excimer laser will be the Amaris (Schwind eye-tech-solutions, Mainparkstraße 6-10, 63801 Kleinostheim, Germany), responsible for performing refractive correction on the cornea through selective photoablation. Following photoablation, the flap will be carefully repositioned, and upon completion o

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: KLEx
Description: For the KLEx technique, the following steps will be followed: after topical anesthesia, a sterile drape is placed over the patient, and a speculum is inserted into the eye, centered, and aligned with a curved interface cone before applying suction. The laser used will be the ATOS operating system (Schwind eye-tech-solutions, Mainparkstraße 6-10, 63801 Kleinostheim, Germany), which performs photo-dissection starting from the posterior surface of the refractive lenticule, followed by the creation of the lenticule edge. The anterior surface of the refractive lenticule is formed by extending beyond the posterior diameter of the lenticule by 0.5 mm to form the anterior flap, followed by a peripheral cut. Specific FS laser parameters are employed for each patient. Subsequently, the suction is released, and a Siebel spatula is used to separate and reflect the flap. Finally, the refractive lenticule is extracted using toothless forceps through the small incision. Once the procedure is complete
Study: NCT05355909

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Individualized high intensity preoperative fitness training
Description: The individualised training program consists of stamina training, interval training and strength training. The personalised fitness training will be designed based on the FITT-VP (frequency, intensity, time, type, volume, progression) of the American College of Sports Medicine (ACSM) and will contain 6 training session within 2 weeks under supervision of professional sport physicians.
Study: NCT05686447

Intervention type: OTHER
Intervention: Observational studies, no intervention
Description: Observational studies, no intervention

Intervention type: OTHER
Intervention: Observational studies, no intervention
Description: Observational studies, no intervention
Study: NCT05002166

Intervention type: OTHER
Intervention: labortatory such as fecal calprotectin ,CRP,CBC,ESR. Endoscopic examination of the gastrointestinal tract Histological examination of the biopsies retrieved during gastrointestinal endoscope.
Description: labortatory such as fecal calprotectin ,CRP,CBC,ESR. Endoscopic examination of the gastrointestinal tract Histological examination of the biopsies retrieved during gastrointestinal endoscope.
Study: NCT05947500

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tuvusertib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tuvusertib
Description: Given PO
Study: NCT05844332

Intervention type: OTHER
Intervention: LUTATHERA
Description: There is no treatment allocation. Patients administered LUTATHERA by prescription can be enrolled.
Study: NCT05667857

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrative neurocognitive remediation therapy
Description: Integrative Neurocognitive Remediation Therapy is a clinical program of 12 weeks (1 day/week) that combines personalized computerized cognitive training and neurocognitive strategy training, with group sessions of adapted physiotherapy, acceptance and commitment therapy (ACT), cognitive behavioral therapy (CBT) and information sessions on cognition, fatigue, nutrition and physical exercise.
Study: NCT04849845

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Afrezza Dose 1
Description: The first dose of Afrezza will be based on the dose of subcutaneous rapid-acting analogue (RAA) insulin that the subject would normally take for the standardized meal, converted according to the guidelines provided in the current Afrezza U.S. prescribing information.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Afrezza Dose 2
Description: The second dose of Afrezza will be based on the dose of subcutaneous rapid-acting analogue that the subject would normally take for the standardized meal, converted by multiplying their RAA dose by 2 and rounding down to the nearest Afrezza cartridge size.
Study: NCT05503004

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prehabilitation
Description: 10 min exercise, 5 min respiratory mindfulness, and preoperative nutrition assessment.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Standard care before surgery
Study: NCT06214377

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Active Transcranial Direct Current Stimulation
Description: The Starstim tCS® equipment will be used, with 35 cm2 sponge electrodes. The tDCS over M1 will be performed by placing the active anode on the C3 point (10/20 EEG system) and the cathode on the contralateral supraorbital area (Fp2). Regarding the stimulated hemisphere, in cases of asymmetric pain, it will be applied to the contralateral M1, and in cases of bilateral pain, it will be applied to the M1 of the dominant hemisphere. A constant current of 2 mA (subthreshold intensity) will be applied for 20 minutes, with the first 30 seconds used as a ramp-up and the last 30 seconds as a ramp-down. Number of sessions: 1.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Transcranial Direct Current Stimulation
Description: The Starstim tCS® equipment will be used, with 35 cm2 sponge electrodes. The tDCS over M1 will be performed by placing the active anode on the C3 point (10/20 EEG system) and the cathode on the contralateral supraorbital area (Fp2). Regarding the stimulated hemisphere, in cases of asymmetric pain, it will be applied to the contralateral M1, and in cases of bilateral pain, it will be applied to the M1 of the dominant hemisphere. A constant current of 2 mA (subthreshold intensity) will be applied for 20 minutes, with the first 30 seconds used as a ramp-up and the last 30 seconds as a ramp-down. Number of sessions: 1.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial Direct Current Stimulation
Description: The Starstim tCS® equipment (Neuroelectrics Inc, Barcelona, Spain) will be used with 35 cm2 sponge electrodes. The tDCS sham over M1 will be performed by placing the electrodes in the same position as in the active tDCS protocol. However, the stimulator will automatically turn off after 30 seconds of stimulation, making it a reliable sham stimulation method. Therefore, subjects will feel the same tingling sensation but will not receive current for the remainder of the stimulation time.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham Transcranial Direct Current Stimulation
Description: The Starstim tCS® equipment (Neuroelectrics Inc, Barcelona, Spain) will be used with 35 cm2 sponge electrodes. The tDCS sham over M1 will be performed by placing the electrodes in the same position as in the active tDCS protocol. However, the stimulator will automatically turn off after 30 seconds of stimulation, making it a reliable sham stimulation method. Therefore, subjects will feel the same tingling sensation but will not receive current for the remainder of the stimulation time.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Dopaminergic medication
Description: After tDCS, the participant will take their regular dopaminergic medication in order to go from OFF state to ON state.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dopaminergic medication
Description: After tDCS, the participant will take their regular dopaminergic medication in order to go from OFF state to ON state.
Study: NCT05905848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: administering RASI (the trade name or universal name will not be stipulated) before stenting
Description: Pre-operative antihypertensive drugs before stenting will be random assigned (RASI or CCB) at least 5 days before stenting. Patients in RASI group will receive RASI (all kinds of RASI will be permited and the trade name or universal name of drugs will not be limited), with or without other antihypertensives except for CCB (any kind of CCB).~Blood pressure of patients should be controlled within the target range (140/90 mmHg); and usage and dosage of antihypertensive drugs will not be stipulated. Grapefruit intaking should be avoid.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: administering CCB (the trade name or universal name will not be stipulated) before stenting
Description: Pre-operative antihypertensive drugs before stenting will be random assigned (RASI or CCB) at least 5 days before stenting. Patients in CCB group will receive CCB (all kinds of CCB will be permited and the trade name or universal name of drugs will not be limited), with or without other antihypertensives except for RASI (any kind of RASI).~Blood pressure of patients should be controlled within the target range (140/90 mmHg); and usage and dosage of antihypertensive drugs will not be stipulated. Grapefruit intaking should be avoid.
Study: NCT05348109

Intervention type: OTHER
Intervention: Well finished cases
Description: To decide whether extraction or non-extraction decision will be made for each case
Study: NCT05418348

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GTX-104
Description: new formulation of nimodipine injection for IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimodipine Capsules
Description: Nimodipine capsules (reference formulation)
Study: NCT06394102

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The automatic color temperature adjustment mode equipped on terminal display devices can reduce the discrepancy between the color temperature of the device and the ambient light.
Description: A program mode on a terminal display device that reduces the difference between the color temperature of the ambient light and that of the display device.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The automatic color temperature adjustment mode equipped on terminal display devices can reduce the discrepancy between the color temperature of the device and the ambient light.
Description: A program mode on a terminal display device that reduces the difference between the color temperature of the ambient light and that of the display device.
Study: NCT04933513

Intervention type: BEHAVIORAL
Intervention: pre DBS patients responding to the DBS-PS scale
Description: we propose to parkinson's disease patients selected for subthalamic deep brain stimulation to complete the DBS-PS scale preoperatively
Study: NCT04747249

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychological support
Description: Psychological care will be based on a monthly interview lasting approximately 45 minutes for 6 months.
Study: NCT05033925

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: FADA (active fraction of Ficus septica leaf) 800 mg/day
Description: FADA is given twice a day (total dose of 800 per day per patient)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: FADA (active fraction of Ficus septica leaf) 2000 mg/day
Description: FADA is given twice a day (total dose of 2000 per day per patient)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule
Description: Placebo capsule is given twice a day
Study: NCT06391359

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Description: Laparoscopic cholecystectomy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Watchful waiting
Description: Watchful waiting
Study: NCT05084183

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PermeaDerm®
Description: Wound Management Device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mepilex Ag
Description: Wound Dressing
Study: NCT06338397

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SCANN
Description: Administering 11 tests of social \& affective cognition to each participant as well as 6 scales to their study-partner, in order to have a detailed profile of social \& affective cognitive abilities that we can correlate to an 3DMRI with resting state procedure.
Study: NCT06422871

Intervention type: DEVICE
Intervention: HeRO® Graft System or Super HeRO® System
Description: Treatment attempted with the HeRO® or Super HeRO® device.
Study: NCT04332003

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Remote Ischemic Conditioning (RIC) Treatment
Description: RIC treatment will be delivered by an automated device that delivers the RIC treatment (manufactured by LifeCuff Technologies).
Study: NCT05909267

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-dopa/Carbidopa
Description: Patients and healthy controls will receive one time administration of L-dopa/Carbidopa (100/25 mg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-dopa/Carbidopa
Description: Patients and healthy controls will receive one time administration of L-dopa/Carbidopa (100/25 mg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Patients and healthy controls will receive one time administration of Placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Patients and healthy controls will receive one time administration of Placebo.
Study: NCT06454006

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo PBMT-sMF
Description: Placebo, without therapeutic dose.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active PBMT-sMF
Description: Active with a dose of 31.50 J per site.
Study: NCT06455020

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Catheter ablation
Description: Emergency catheter ablation is defined as ablation performed within 48 hours of hospital admission

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stepped-care strategies
Description: Patients randomized to the stepped-care strategy arm will receive treatment through a systematic, stepwise protocol beginning with anti-arrhythmic drugs, followed by sedation and anesthesia, and progressing to haemodynamic mechanical support devices if earlier treatments prove ineffective. Catheter ablation will be reserved as the final rescue intervention.
Study: NCT05945199

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: tDCS
Description: * 1 session/day for 5 consecutive days~* stimulation at an intensity of 2 mA for the active tDCS group and sham stimulation (using the device's sham mode) for the placebo group

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: * 1 session/day for 5 consecutive days~* stimulation at an intensity of 2 mA for the active tDCS group and sham stimulation (using the device's sham mode) for the placebo group

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Assessment of risk behaviours
Description: Assessment of risk behaviours (retrospective exploration by the categorical rating of frequency: At least once a day - Several times a week several times a week - once a week - several times a month - once a month - less than once a month - never). times a month - Once a month - Less than once a month - Never)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assessment of risk behaviours
Description: Assessment of risk behaviours (retrospective exploration by the categorical rating of frequency: At least once a day - Several times a week several times a week - once a week - several times a month - once a month - less than once a month - never). times a month - Once a month - Less than once a month - Never)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Scales
Description: EVA craving index for chemsex Maximum VAS craving in the week preceding assessment for chemsex, sexual practices and use of psychoactive substances, HAqII, CSBD-19, modified CCQ-brief, SDI, BDI-II

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scales
Description: EVA craving index for chemsex Maximum VAS craving in the week preceding assessment for chemsex, sexual practices and use of psychoactive substances, HAqII, CSBD-19, modified CCQ-brief, SDI, BDI-II
Study: NCT05522010

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cervical spine surgery
Description: A standard anterior approach was made with discectomy sparing the cartilage, and with foraminal decompression. Complete excision of the posterior longitudinal ligament was routinely performed to complete neural decompression. Trial inserters were used to identify the proper implant size. Device under sizing may lead to poor ﬁxation and implant migration. The largest possible device that can be safely placed should be selected to maximize device- endplate contact and to gain support from the apophyseal rim. The teeth of the implant were optimally ﬁxated to the endplate via Caspar pin compression following device insertion. The device may be replaced or changed using the same insertion instrument if ﬁnal imaging demonstrated suboptimal positioning. Rinsing the implanted disc space removes rests of blood and bone dust, all potentially promoting HO

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cervical spine surgery
Description: A standard anterior approach was made with discectomy sparing the cartilage, and with foraminal decompression. Complete excision of the posterior longitudinal ligament was routinely performed to complete neural decompression. Trial inserters were used to identify the proper implant size. Device under sizing may lead to poor ﬁxation and implant migration. The largest possible device that can be safely placed should be selected to maximize device- endplate contact and to gain support from the apophyseal rim. The teeth of the implant were optimally ﬁxated to the endplate via Caspar pin compression following device insertion. The device may be replaced or changed using the same insertion instrument if ﬁnal imaging demonstrated suboptimal positioning. Rinsing the implanted disc space removes rests of blood and bone dust, all potentially promoting HO
Study: NCT05258253

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intensity aerobics
Description: London bridges (8mins) Jumping lunges(8mins) Mountain climbers(8mins) Quadruped bent knee hip extension (8mins)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic clock exercises
Description: Lie with your back on the floor in a neutral position with your legs bent and toes facing forward. Subject begin with gentle movements from 12 to 6 o'clock, as instructed to move from 3 o'clock to 9 o'clock. Then move in a clockwise manner from 12 to 3 to 6 to 9 and then back to 12 o' clock.
Study: NCT05907798

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: LIMA Blood flow
Description: 30 minutes after induction

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LIMA Blood flow
Description: 30 minutes after induction

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LIMA Blood flow
Description: 30 minutes after induction